To test the potential for PKCε and p53 to express a functional relationship in vivo, and in the absence of PKCε-selective drugs with suitable pharmacokinetic properties, we sought to test the impact of PKCε loss on tumours driven by p53 loss. The gene discussed is PRKCE; the disease is neoplasm.